Psychedelic-Assisted Therapy in Hospice and End-of-Life Care: What Is Legally Available?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Patients with terminal or life-limiting diagnoses, their families, hospice and palliative care providers, and anyone trying to understand what legal pathways currently exist for psilocybin access in an end-of-life context.

The short answer

Terminal illness does not create a special legal pathway to psilocybin in the United States. There is no federal compassionate-use exception, no Right to Try route that currently works, and no prescription pathway for psilocybin through the conventional medical system. What does exist: the Oregon and Colorado state-licensed programs, which are open to all eligible adults regardless of health status; the New Mexico program, which explicitly covers end-of-life care but is not yet enrolling patients; authorized clinical trials that sometimes specifically include end-of-life populations; and, for people able to travel, regulated access in a small number of other countries.

The federal picture

Psilocybin is Schedule I under the Controlled Substances Act. For a physician to administer a Schedule I substance outside of a research context, the physician must hold a Schedule I researcher registration from the DEA, and the use must occur within a federally authorized research study. There is no prescription pathway. No physician in the United States can legally prescribe psilocybin to a patient the way they prescribe opioids, ketamine, or other controlled substances.

This restriction applies regardless of the severity of the patient’s condition. A physician treating a patient with stage IV cancer cannot legally obtain and administer psilocybin to that patient under federal law simply because the patient is terminal.

Right to Try does not change this

The federal Right to Try Act, enacted in 2018, was designed to give terminally ill patients who have exhausted approved treatment options access to investigational drugs that have completed Phase 1 clinical trials but have not yet received FDA approval. Psilocybin has completed Phase 1 trials and holds FDA Breakthrough Therapy designation for treatment-resistant depression and major depressive disorder.

The argument that psilocybin qualifies as an eligible investigational drug under the Right to Try Act was litigated directly by the Advanced Integrative Medical Science Institute (AIMS) and Dr. Sunil Aggarwal, a Seattle palliative care physician, in AIMS et al. v. DEA, No. 22-1568. Dr. Aggarwal sought either a determination from the DEA that his proposed psilocybin therapy for terminally ill patients did not require Schedule I registration, or alternatively a waiver of that requirement under DEA’s authority in 21 U.S.C. § 822(d). The DEA denied both requests. On February 13, 2025, the Ninth Circuit Court of Appeals upheld the DEA’s denial. The court found that the Right to Try Act does not modify the CSA’s registration requirements — the RTT exempts FDA approval, but it does not exempt DEA oversight under the CSA. A physician who wants to administer psilocybin to a terminally ill patient outside of research still needs a Schedule I researcher registration, and that registration is for research, not compassionate clinical care.

As of early 2026, this ruling stands. Legislative proposals to address it — including the Freedom to Heal Act introduced in December 2025 — have been introduced but not enacted.

State-licensed programs: available now

Oregon

Oregon’s licensed psilocybin services program does not restrict access based on health status or diagnosis. A terminally ill adult 21 or older — including a non-resident — can access a supervised session at a licensed service center on the same terms as any other adult. No referral is required. No diagnosis is required. No physician’s involvement is required.

This creates a practical access route for end-of-life patients who can travel to Oregon, complete a preparation session with a licensed facilitator, and attend an on-site administration session. The practical barriers are real: cost (typically $1,000–$3,000 or more, all out of pocket), the need to travel and remain on-site for a multi-hour session, and the physical demands of the experience itself. A patient who is significantly debilitated by illness may find these logistics difficult or impossible.

Oregon service centers operate under state law only. Participation does not create any federal legal protection, and a licensed facilitator is not the same as a physician or therapist. Facilitators are trained and licensed by the state but are not required to hold mental health credentials.

Colorado

Colorado’s licensed healing center program follows similar rules. Adults 21 and older may access supervised psilocybin sessions without a diagnosis or prescription. Colorado also established a clinical facilitator track for licensed mental and medical health professionals, which allows more clinically integrated delivery. A terminal patient working with a physician who also holds a Colorado clinical facilitator credential could potentially receive more integrated care than the general facilitator track provides.

The same practical barriers — cost, travel, on-site requirements, physical tolerability — apply.

New Mexico

New Mexico’s Medical Psilocybin Act, signed April 7, 2025, explicitly lists end-of-life care as a qualifying condition. Unlike Oregon and Colorado, New Mexico’s program is a medical model requiring a qualifying diagnosis from a licensed healthcare provider. End-of-life care is one of four qualifying conditions named in the statute, alongside major treatment-resistant depression, PTSD, and substance use disorders.

The New Mexico program is not yet enrolling patients. The Department of Health is building the regulatory infrastructure, with a statutory deadline of December 31, 2027 for full implementation and a stated goal of enrolling the first patients by the end of 2026. End-of-life patients who cannot wait should look to Oregon or Colorado rather than New Mexico.

Clinical trials

Clinical trials remain a legal pathway for some end-of-life patients. Several trials have specifically studied psilocybin in cancer patients experiencing existential distress, anxiety, and depression. These trials use FDA-authorized Investigational New Drug Applications and DEA Schedule I researcher registrations. The substance is administered at the research site under study protocols.

Eligibility is typically narrow and involves medical screening, exclusion criteria, and a significant time commitment. Patients with very limited life expectancy may not be able to complete a multi-month trial. ClinicalTrials.gov lists currently enrolling psilocybin trials, including those with end-of-life or oncology populations. Reaching out to academic medical centers with active psychedelic research programs — Johns Hopkins, NYU, UCSF, and others — is a practical way to identify currently enrolling studies.

Clinical trials are generally free to participants, though travel and logistical costs are not always covered.

What hospice and palliative care providers can and cannot do

A hospice physician, palliative care nurse, or mental health professional working in an end-of-life context cannot prescribe, administer, or facilitate access to psilocybin through the conventional healthcare system under federal law. Doing so outside of a properly authorized research context would expose the provider to DEA enforcement, loss of DEA registration, and potential professional licensing consequences.

A provider can discuss psilocybin, describe the research, explain the Oregon and Colorado state programs, and support a patient’s decision to seek access through legal channels. Referring a patient to an Oregon or Colorado service center is not itself a legal risk for the provider. Obtaining psilocybin and administering it to a patient outside of a DEA-registered research context is.

Colorado’s clinical facilitator track, if the provider obtains the required state licensure and operates within the state program, provides a route for healthcare professionals to integrate psilocybin services within their existing practice. This does not create federal authorization but does provide state-law compliance within Colorado.

Practical considerations for terminal patients and families

The most accessible legal options right now are Oregon’s and Colorado’s programs for patients who can travel and tolerate an on-site experience. The cost and logistics are real barriers. Some Oregon service centers offer sliding-scale pricing, and it is worth asking directly. Hospice and palliative care social workers may have information about providers with experience working with seriously ill clients.

For patients enrolled in or eligible for clinical trials, that route provides federal authorization and medical oversight, which may matter for patients with complex medical situations where close monitoring is important.

For patients in New Mexico who are anticipating the program’s eventual launch, monitoring the Department of Health’s psilocybin program page is the most direct way to track when enrollment begins.

When public information may be enough

If your question is what legal options currently exist for end-of-life psilocybin access, this article covers the current state of law. For the Right to Try Act in full detail, What is the Right to Try Act and does it apply to psychedelics? covers how the law works and what the AIMS v. DEA ruling established. For what clinical trials involve, Clinical trials vs. legal access programs: what’s the difference? explains how they work and what participation requires. For Oregon’s program specifically, Oregon psilocybin services explained for clients covers the process, cost, and logistics. For how the FDA approval process connects to access, What FDA approval does and does not mean for psychedelic treatments addresses that directly. For what to bring to a first legal consultation, What to gather before booking a consult with a psychedelic lawyer explains what information matters.

When you should speak with a lawyer

You should speak with a lawyer if:

You are a hospice or palliative care provider who wants to understand what you can legally say or do in relation to psilocybin access for your patients
You are a patient or family member trying to understand whether a specific provider or program you have been referred to is operating within a legal framework
You are considering accessing psilocybin through an informal or unregulated channel and want to understand the legal risks
You are a healthcare organization evaluating whether to build psilocybin services into an end-of-life care program and need to understand the licensing, liability, and federal law issues

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.